Indeed, neutralization of IL-1 with antibodies or natural antagonists (i.e. IL-1RA or IL-1R2) diminish local inflammation and protect the joint from bone erosion, which led to the approval of Anakinra (IL-1RA) as an effective therapeutic for management of RA (259–261). The gene discussed is IL1A; the disease is rheumatoid arthritis.